---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000023"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:30:57.409829+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics appoints Dr. Bernhardt Zeiher to Board of Directors

## Summary
- Board expanded from 7 to 8; Dr. Zeiher appointed as Class II director and to Nominating and Corporate Governance Committee.
- Dr. Zeiher most recently served as Chief Medical Officer at Astellas Pharma; brings clinical and regulatory expertise.
- Received initial option for 32,000 shares vesting over 3 years; annual director fee of $40,000 plus committee fee.
- Entrada's lead programs include Duchenne muscular dystrophy and myotonic dystrophy type 1.

## SEC filing metadata
- accession: 0001689375-23-000023
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000023/0001689375-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000023/trda-20230404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000023
- JSON: https://secwatch.observer/filing/0001689375-23-000023.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000023.txt

## Key facts
- Executive change
  Bernhardt Zeiher was appointed as Director at Entrada Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective as of April 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Bernhardt Zeiher, M.D. to the Board as a Class II director, to serve until the annual meeting of stockholders held in 2023 or until his successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000023/0001689375-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.